Sponsored For
Beginners Choice

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
HubSpot, Inc is a software-application business based in the US. HubSpot shares (HUBS) are listed on the NYSE and all prices are listed in US Dollars. HubSpot employs 3,981 staff and has a trailing 12-month revenue of around USD$817.1 million.
52-week range | USD$90.835 - USD$420.61 |
---|---|
50-day moving average | USD$393.7018 |
200-day moving average | USD$316.7702 |
Wall St. target price | USD$413.87 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-1.468 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the last close of $N/A
1 week (2021-01-13) | N/A |
---|---|
1 month (2020-12-20) | N/A |
3 months (2020-10-20) | N/A |
6 months (2020-07-20) | N/A |
1 year (2020-01-20) | N/A |
---|---|
2 years (2019-01-20) | N/A |
3 years (2018-01-20) | N/A |
5 years (2016-01-20) | N/A |
Valuing HubSpot stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of HubSpot's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
HubSpot's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 9.3964. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into HubSpot's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Revenue TTM | USD$817.1 million |
---|---|
Gross profit TTM | USD$544.9 million |
Return on assets TTM | -1.89% |
Return on equity TTM | -11.74% |
Profit margin | -9.78% |
Book value | $16.036 |
Market capitalisation | USD$18.1 billion |
TTM: trailing 12 months
There are currently 1.1 million HubSpot shares held short by investors – that's known as HubSpot's "short interest". This figure is 16.8% down from 1.3 million last month.
There are a few different ways that this level of interest in shorting HubSpot shares can be evaluated.
HubSpot's "short interest ratio" (SIR) is the quantity of HubSpot shares currently shorted divided by the average quantity of HubSpot shares traded daily (recently around 630408.09248555). HubSpot's SIR currently stands at 1.73. In other words for every 100,000 HubSpot shares traded daily on the market, roughly 1730 shares are currently held short.
However HubSpot's short interest can also be evaluated against the total number of HubSpot shares, or, against the total number of tradable HubSpot shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case HubSpot's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 HubSpot shares in existence, roughly 20 shares are currently held short) or 0.0285% of the tradable shares (for every 100,000 tradable HubSpot shares, roughly 29 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against HubSpot.
Steps to owning and managing Vaxart shares from Ireland.
Steps to owning and managing Takeda Pharmaceutical shares from Ireland.
Steps to owning and managing Sinovac Biotech Ltd shares from Ireland.
Steps to owning and managing Mesoblast shares from Ireland.
Steps to owning and managing Inovio Pharmaceuticals shares from Ireland.
Steps to owning and managing Heat Biologics shares from Ireland.
Steps to owning and managing CytoDyn shares from Ireland.
Steps to owning and managing Cynata Therapeutics shares from Ireland.
Steps to owning and managing BioNTech shares from Ireland.
Steps to owning and managing Atomo Diagnostics shares from Ireland.